Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,340
+39.61%
|
-
|
|
Feb 21
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Open market or private sale
|
Direct |
8,000
-46.87%
|
$2,000,000
$250.58 P/Share
|
|
Feb 21
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+14.95%
|
$546,000
$182.51 P/Share
|
|
Feb 14
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
309
-4.42%
|
$76,323
$247.63 P/Share
|
|
Feb 13
2023
|
Jean Luc Belingard Director |
SELL
Payment of exercise price or tax liability
|
Direct |
75
-0.44%
|
$18,600
$248.13 P/Share
|
|
Feb 13
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.42%
|
$21,080
$248.13 P/Share
|
|
Feb 13
2023
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-4.8%
|
$290,160
$248.13 P/Share
|
|
Feb 13
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
195
-0.54%
|
$48,360
$248.13 P/Share
|
|
Feb 13
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
142
-1.0%
|
$35,216
$248.13 P/Share
|
|
Feb 13
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-0.75%
|
$30,752
$248.13 P/Share
|
|
Feb 13
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-1.39%
|
$19,344
$248.13 P/Share
|
|
Feb 13
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
54
-7.13%
|
$13,392
$248.13 P/Share
|
|
Feb 13
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
69
-3.39%
|
$17,112
$248.13 P/Share
|
|
Feb 13
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
114
-1.6%
|
$28,272
$248.13 P/Share
|
|
Feb 13
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38
-1.73%
|
$9,424
$248.13 P/Share
|
|
Feb 11
2023
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+4.18%
|
-
|
|
Feb 11
2023
|
Kerrii B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+3.53%
|
-
|
|
Feb 11
2023
|
Garheng Kong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+6.35%
|
-
|
|
Feb 11
2023
|
Dwight Gary Gilliland Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+8.72%
|
-
|
|
Feb 11
2023
|
Jeffrey A. Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+21.73%
|
-
|
|
Feb 11
2023
|
Kathryn E Wengel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+35.55%
|
-
|
|
Feb 11
2023
|
Richelle P Parham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+8.91%
|
-
|
|
Feb 11
2023
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+6.32%
|
-
|
|
Feb 11
2023
|
R Sanders Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
742
+9.37%
|
-
|
|
Feb 11
2023
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
290
+1.41%
|
-
|
|
Feb 11
2023
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,656
+9.83%
|
-
|
|
Feb 11
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
723
+1.98%
|
-
|
|
Feb 11
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
483
+3.29%
|
-
|
|
Feb 11
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
423
+2.49%
|
-
|
|
Feb 11
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
290
+4.9%
|
-
|
|
Feb 11
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
180
+19.21%
|
-
|
|
Feb 11
2023
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
236
+10.4%
|
-
|
|
Feb 11
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
423
+5.62%
|
-
|
|
Feb 11
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
110
+4.77%
|
-
|
|
Feb 07
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
219
-3.94%
|
$53,217
$243.01 P/Share
|
|
Feb 07
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
409
-5.76%
|
$99,387
$243.01 P/Share
|
|
Feb 06
2023
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,368
-5.93%
|
$333,792
$244.5 P/Share
|
|
Feb 06
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-2.08%
|
$36,844
$244.5 P/Share
|
|
Feb 06
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
164
-1.18%
|
$40,016
$244.5 P/Share
|
|
Feb 06
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-0.74%
|
$63,684
$244.5 P/Share
|
|
Feb 06
2023
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.54%
|
$26,352
$244.5 P/Share
|
|
Feb 06
2023
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
164
-1.01%
|
$40,016
$244.5 P/Share
|
|
Feb 06
2023
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
52
-2.43%
|
$12,688
$244.5 P/Share
|
|
Feb 06
2023
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-1.44%
|
$19,764
$244.5 P/Share
|
|
Feb 06
2023
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-12.58%
|
$20,252
$244.5 P/Share
|
|
Feb 06
2023
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-4.47%
|
$20,496
$244.5 P/Share
|
|
Feb 04
2023
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,507
+13.2%
|
-
|
|
Feb 04
2023
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+7.17%
|
-
|
|
Feb 04
2023
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+3.87%
|
-
|
|
Feb 04
2023
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
970
+2.67%
|
-
|